New Vaccine for Melanoma Developed by Tel Aviv University Scientists

Understanding Melanoma

Melanoma is the most rapidly increasing form of skin cancer, originating from melanocytes, the cells responsible for producing melanin, or skin pigment. Current treatment options for melanoma include chemotherapy, radiation therapy, and immunotherapy.

Innovative Immunotherapy Approach

Researchers at Tel Aviv University have introduced a groundbreaking approach to melanoma treatment by developing a vaccine that utilizes immunotherapy. This method aims to enhance the body’s own immune response. Despite its potential, immunotherapy can lead to severe side effects, inadequate responses, and the onset of drug resistance, underscoring the necessity for further clinical trials and research.

Immunotherapy Vaccine Research

The research team combined their new vaccine with specific antibodies and conducted tests on mice. The anti-PD-1 antibody was utilized to prevent immune system suppression, while the anti-OXO antibody was included to boost the quantity and longevity of immune cells known as T cells. This combination resulted in improved efficacy in treating melanoma, although it did not exhibit additional tumor growth inhibition compared to treatment with antibodies alone. However, when the vaccine and antibodies were paired with ibrutinib, a drug that counteracts immunosuppression, a notable reduction in melanoma intensity and extended survival rates were observed.

Benefits of the Vaccine

The newly developed vaccine, in conjunction with immunotherapy, demonstrated effectiveness in slowing the progression of melanoma. It also showed prophylactic benefits, as mice treated with the vaccine did not develop melanoma. Moreover, the vaccine proved successful when tested on tissues from patients with melanoma that had metastasized to the brain.

Future Implications

This melanoma vaccine presents a promising treatment option for individuals battling this aggressive cancer. The study marks a significant scientific advancement, introducing a novel strategy for cancer prevention and treatment. As stated by Prof. Satchi-Fainaro, “Our research opens the door to a completely new approach, the vaccine approach, for effective treatment of melanoma, even in the most advanced stages of the disease. We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”

References

1. Conniot J, Scomparin A, Peres C, et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019;14(9):891-901. doi:10.1038/s41565-019-0512-02.
2. Hunka G. Tel Aviv University scientists develop novel nano-vaccine for melanoma. EurekAlert! August 5, 2019. Accessed August 8, 2019. https://sciencesources.eurekalert.org/news-releases/846983.